Streetwise Articles



Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Source: Streetwise Reports  (3/27/24)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock. More >


AI Co. Funded To Develop AI Approach to Health Equity
Source: Streetwise Reports  (3/27/24)
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock. More >


AI Medical App Passes Standard Student Test
Source: Streetwise Reports  (3/26/24)
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector. More >


Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says
Source: Dr. Douglas Loe  (3/26/24)
K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note. More >


Biotech Co.'s Target Price Significantly Higher Than Current
Source: Dr. Jonathan Aschoff  (3/19/24)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note. More >


Ron Struthers

Biotech Stocks Break Out
Source: Ron Struthers  (3/19/24)
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into. More >


Is This Pharma Set To Break Out After COPD Drug Approval?
Source: Streetwise Reports  (3/15/24)
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024. More >


Chris Temple

This Biotech Is a Potential Disruptor, Expert Says
Source: Chris Temple  (3/12/24)
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy. More >


Wellness Co.'s New Initiatives Should 'Lower Barriers' Analysts Say
Source: George Kelly  (3/12/24)
The Beachbody Company Inc.'s 4Q23 results have Roth MKM analysts maintaining their Buy rating. More >


Safe Supply Firm Announces Another Promising Acquisition
Source: Streetwise Reports  (3/11/24)
Safe Supply Streaming Co. adds another company to its portfolio, and continues advocating for harm reduction in the psychedelic sector. More >


Healthcare AI Firm Has 'Bright Future,' Analyst Predicts
Source: Streetwise Reports  (3/8/24)
Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade. More >


NY Biotech Has Potentially Game Changing Anxiety Therapy
Source: Dr. Jonathan Aschoff  (3/7/24)
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note. More >


Bionic Medical Co. Has Sufficient Funds to Operate Through 2024
Source: Dr. Swayampakula Ramakanth  (3/5/24)
Ekso Bionics Holdings Inc.'s fourth quarter of 2023 financial results were in line with estimates, according to H.C. Wainwright & Co. More >


'Safe Supply' Co. Secures Legal Flow of Coca Products
Source: Streetwise Reports  (2/20/24)
This is a milestone for the venture capital firm investing in efforts that address the toxic drug crisis in Canada and the U.S. Learn more about the company and the latest wave of drug reform. More >


Alt-Pharma VC adds 7% Stake in Testing Strip Firm
Source: Streetwise Reports  (2/15/24)
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio. More >


Ron Struthers

Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says
Source: Ron Struthers  (2/12/24)
Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly. More >


Wellness Co. Preparing for US Legislation
Source: Bill Kirk  (2/12/24)
Wellness company Canopy Growth Corp. is taking steps forward while it waits for the U.S. to make legislative changes, according to a Roth MKM research note. More >


Drug Reformer Subsidiary Inspected for Dealer License
Source: Streetwise Reports  (2/2/24)
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances. More >


Leadership Cuts Won't Slow This Biotech
Source: Robert Burns  (1/26/24)
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report. More >


Pharma Co. Primed for Future Business
Source: Dr. Andre Uddin  (1/25/24)
Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development. More >


Healthcare Co. Exceeds Expectations in Performance
Source: Dr. Yi Chen  (1/24/24)
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note. More >


Innovator in Drug Policy Now Listed on the OTCQBA Venture Market
Source: Streetwise Reports  (1/18/24)
Safe Supply Streaming Co. Ltd. Announced that it is expanding availability for potential investors. Read on to see why this stock might represent an opportunity as drug policy changes. More >


Pharma Co. Invests in Clinical Psychedelics
Source: Streetwise Reports  (1/17/24)
ATAI Life Sciences N.V. has announced that it is investing in psychedelic treatments for Major Depressive Disorder and Alcohol Use Disorder. Read on to see why one analyst likes this company's stock. More >


Money Manager: The Year of Small Caps?
Source: Streetwise Reports  (1/16/24)
The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps. More >


Big Pharma's Looming Patents May Benefit One Biotech
Source: Streetwise Reports  (1/10/24)
Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024. More >


Showing Results: 1 to 25 of 2469 Next

Notable Quotes

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts